Target- |
MechanismGene transference |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD), First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy ofmEphA4-Fc in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis (ALS)
100 Clinical Results associated with NuNerve Pty Limited
0 Patents (Medical) associated with NuNerve Pty Limited
100 Deals associated with NuNerve Pty Limited
100 Translational Medicine associated with NuNerve Pty Limited